PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32060401-2	2020	MEDI2228, more effectively than its anti-tubulin MMAF-ADC homolog, induces cytotoxicity against MM cells regardless of drug resistance, BCMA levels, p53 status, and the protection conferred by bone marrow stromal cells and IL-6.	medi2228	0-8	tumor protein p53	Homo sapiens	149-152
34301753-0	2021	BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression.	medi2228	18-26	TNF receptor superfamily member 17	Homo sapiens	0-4
34301753-0	2021	BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression.	medi2228	18-26	interferon alpha 1	Homo sapiens	87-90
34301753-0	2021	BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression.	medi2228	18-26	CD38 molecule	Homo sapiens	128-132
34301753-2	2021	We here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by BCMA pyrrolobenzodiazepine (PBD) antibody drug conjugate MEDI2228 which can augment efficacy of these immunotherapies.	medi2228	169-177	TNF receptor superfamily member 17	Homo sapiens	112-116
34301753-8	2021	In vitro and in vivo upregulation of NKG2D ligands and CD38 in MEDI2228-treated MM cells was further associated with synergistic Daratumumab (Dara) CD38 MoAb triggered NK-mediated cytotoxicity of both cell lines and autologous drug resistant patient MM cells.	medi2228	63-71	killer cell lectin like receptor K1	Homo sapiens	37-42
34301753-8	2021	In vitro and in vivo upregulation of NKG2D ligands and CD38 in MEDI2228-treated MM cells was further associated with synergistic Daratumumab (Dara) CD38 MoAb triggered NK-mediated cytotoxicity of both cell lines and autologous drug resistant patient MM cells.	medi2228	63-71	CD38 molecule	Homo sapiens	55-59
32060401-2	2020	MEDI2228, more effectively than its anti-tubulin MMAF-ADC homolog, induces cytotoxicity against MM cells regardless of drug resistance, BCMA levels, p53 status, and the protection conferred by bone marrow stromal cells and IL-6.	medi2228	0-8	interleukin 6	Homo sapiens	223-227
32060401-3	2020	Distinctly, prior to apoptosis, MEDI2228 activates DDRs in MM cells via phosphorylation of ATM/ATR kinases, CHK1/2, CDK1/2, and H2AX, associated with expression of DDR-related genes.	medi2228	32-40	ATM serine/threonine kinase	Homo sapiens	91-106
32060401-3	2020	Distinctly, prior to apoptosis, MEDI2228 activates DDRs in MM cells via phosphorylation of ATM/ATR kinases, CHK1/2, CDK1/2, and H2AX, associated with expression of DDR-related genes.	medi2228	32-40	checkpoint kinase 1	Homo sapiens	108-114
32060401-3	2020	Distinctly, prior to apoptosis, MEDI2228 activates DDRs in MM cells via phosphorylation of ATM/ATR kinases, CHK1/2, CDK1/2, and H2AX, associated with expression of DDR-related genes.	medi2228	32-40	cyclin dependent kinase 12	Homo sapiens	116-122
32060401-3	2020	Distinctly, prior to apoptosis, MEDI2228 activates DDRs in MM cells via phosphorylation of ATM/ATR kinases, CHK1/2, CDK1/2, and H2AX, associated with expression of DDR-related genes.	medi2228	32-40	H2A.X variant histone	Homo sapiens	128-132
32060401-5	2020	Moreover, suboptimal doses of MEDI2228 and bortezomib (btz) synergistically trigger apoptosis of even drug-resistant MM cells partly via modulation of RAD51 and accumulation of impaired DNA.	medi2228	30-38	RAD51 recombinase	Homo sapiens	151-156